Charlie N. Fong
Inversor de Capital Privado en BDC Venture Capital .
Perfil
Dr. Charlie N.
Fong joined BDC Venture Capital in 1998.
His experience in the pharmaceutical industry encompasses drug discovery, clinical development, marketing, sales training, medical education, business development, strategic partnerships, intellectual property protection, and bioinformatics.
He has held management positions with P&L, for a division of 70 people.
Prior to joining the BDC, Dr. Fong had 10 years of industrial experience with a multinational pharmaceutical company as well as start ups.
Dr. Fong has post-doctoral training from the University of California, Berkeley.
Cargos activos de Charlie N. Fong
| Empresas | Cargo | Inicio |
|---|---|---|
BDC Venture Capital
 BDC Venture Capital Investment ManagersFinance BDC Venture Capital (BDC Venture Capital) is a venture capital firm founded in 1975. The firm is headquartered in Québec, Canada. | Inversor de Capital Privado | 01/01/1998 |
Antiguos cargos conocidos de Charlie N. Fong.
| Empresas | Cargo | Fin |
|---|---|---|
Topigen Pharmaceuticals, Inc.
 Topigen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Topigen Pharmaceuticals, Inc. develops drugs for respiratory diseases. The firm focuses on discovery and development of multiple pathway therapies for respiratory diseases with primary emphasis on asthma, chronic obstructive pulmonary disease, and allergic rhinitis. The company was founded by Paolo Renzi in 2000 and is headquartered in Montréal, Canada. | Director/Miembro de la Junta | - |
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Director/Miembro de la Junta | - |
Formación de Charlie N. Fong.
| University of Ottawa | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 3 |
|---|---|
BDC Venture Capital
BDC Venture Capital Investment ManagersFinance BDC Venture Capital (BDC Venture Capital) is a venture capital firm founded in 1975. The firm is headquartered in Québec, Canada. | Finance |
Aegera Therapeutics, Inc.
Aegera Therapeutics, Inc. BiotechnologyHealth Technology Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics to address major unmet medical needs. Aegera has three programs in clinical development, two for oncology and one for neuropathic pain. Aegera is also dedicated to identifying novel development candidates based upon its core technologies and internal expertise and experience in rapidly moving lead candidates through preclinical development and into clinical trials. | Health Technology |
Topigen Pharmaceuticals, Inc.
Topigen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Topigen Pharmaceuticals, Inc. develops drugs for respiratory diseases. The firm focuses on discovery and development of multiple pathway therapies for respiratory diseases with primary emphasis on asthma, chronic obstructive pulmonary disease, and allergic rhinitis. The company was founded by Paolo Renzi in 2000 and is headquartered in Montréal, Canada. | Health Technology |
- Bolsa de valores
- Insiders
- Charlie N. Fong
